Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

AIMS: Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of dapagliflozin, which lowers systolic blood pressure (SBP),according to baseline SBP in Dapagliflozin and Prev...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Heart J
Autors principals: Serenelli, Matteo, Böhm, Michael, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Solomon, Scott D, DeMets, David L, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Anand, Inder S, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Diez, Mirta, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E A, Verma, Subodh, Docherty, Kieran F, Jhund, Pardeep S, McMurray, John J V
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7550197/
https://ncbi.nlm.nih.gov/pubmed/32820334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa496
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars